author_facet HWU, P.
HWU, P.
author HWU, P.
spellingShingle HWU, P.
Journal of Internal Medicine
Current challenges in cancer gene therapy
Internal Medicine
author_sort hwu, p.
spelling HWU, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.1997.242.s740.109 <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> Current challenges in cancer gene therapy Journal of Internal Medicine
doi_str_mv 10.1111/joim.1997.242.s740.109
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint Wiley, 1997
imprint_str_mv Wiley, 1997
issn 0954-6820
1365-2796
issn_str_mv 0954-6820
1365-2796
language English
mega_collection Wiley (CrossRef)
match_str hwu1997currentchallengesincancergenetherapy
publishDateSort 1997
publisher Wiley
recordtype ai
record_format ai
series Journal of Internal Medicine
source_id 49
title Current challenges in cancer gene therapy
title_unstemmed Current challenges in cancer gene therapy
title_full Current challenges in cancer gene therapy
title_fullStr Current challenges in cancer gene therapy
title_full_unstemmed Current challenges in cancer gene therapy
title_short Current challenges in cancer gene therapy
title_sort current challenges in cancer gene therapy
topic Internal Medicine
url http://dx.doi.org/10.1111/joim.1997.242.s740.109
publishDate 1997
physical 109-114
description <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p>
container_issue S740
container_start_page 109
container_title Journal of Internal Medicine
container_volume 242
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792334397671735302
geogr_code not assigned
last_indexed 2024-03-01T14:27:59.602Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Current+challenges+in+cancer+gene+therapy&rft.date=1997-07-01&genre=article&issn=1365-2796&volume=242&issue=S740&spage=109&epage=114&pages=109-114&jtitle=Journal+of+Internal+Medicine&atitle=Current+challenges+in+cancer+gene+therapy&aulast=HWU&aufirst=P.&rft_id=info%3Adoi%2F10.1111%2Fjoim.1997.242.s740.109&rft.language%5B0%5D=eng
SOLR
_version_ 1792334397671735302
author HWU, P.
author_facet HWU, P., HWU, P.
author_sort hwu, p.
container_issue S740
container_start_page 109
container_title Journal of Internal Medicine
container_volume 242
description <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p>
doi_str_mv 10.1111/joim.1997.242.s740.109
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjE5OTcuMjQyLnM3NDAuMTA5
imprint Wiley, 1997
imprint_str_mv Wiley, 1997
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 0954-6820, 1365-2796
issn_str_mv 0954-6820, 1365-2796
language English
last_indexed 2024-03-01T14:27:59.602Z
match_str hwu1997currentchallengesincancergenetherapy
mega_collection Wiley (CrossRef)
physical 109-114
publishDate 1997
publishDateSort 1997
publisher Wiley
record_format ai
recordtype ai
series Journal of Internal Medicine
source_id 49
spelling HWU, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.1997.242.s740.109 <jats:p>The ability to transfer novel genes into mammalian cells has allowed us to conceive of novel strategies towards cancer therapy. Since the initial gene‐transfer clinical trial in 1989, over 300 cancer patients have been enrolled in gene therapy trials. Despite this, an NIH‐sponsored panel concluded that ‘clinical efficacy has not been definitively demonstrated at this time in any gene therapy protocol’ [1]. However, the first 8 years of gene therapy research have provided us with insights regarding the areas that require further scientific progress. For example, it is now clear that while <jats:italic>in vitro</jats:italic> assays of gene‐modified haemotopoietic progenitor cells suggest high transduction efficiencies, once these cells are infused <jats:italic>in vivo,</jats:italic> only a small percentage of circulating transduced cells can be detected. While the initial clinical studies have demonstrated that gene transfer in patients can be safe and feasible, they have also indicated that future research is necessary towards the development of improved gene transfer techniques for these approaches to be successful.</jats:p> Current challenges in cancer gene therapy Journal of Internal Medicine
spellingShingle HWU, P., Journal of Internal Medicine, Current challenges in cancer gene therapy, Internal Medicine
title Current challenges in cancer gene therapy
title_full Current challenges in cancer gene therapy
title_fullStr Current challenges in cancer gene therapy
title_full_unstemmed Current challenges in cancer gene therapy
title_short Current challenges in cancer gene therapy
title_sort current challenges in cancer gene therapy
title_unstemmed Current challenges in cancer gene therapy
topic Internal Medicine
url http://dx.doi.org/10.1111/joim.1997.242.s740.109